Psychedelic Research Chemicals or RC Chems are new synthetic substances which are structurally similar to the original drug, while being functional analogs. Data on their effects limited due as they’re fairly new and do not have a lot of human consumption history.

Psychedelics are substances (natural or laboratory made) which cause profound changes in a one’s perceptions of reality. While under the influence of hallucinogens, users might hallcuniate visually and auditorily.

Disclaimer: Psychedelic drugs offer some of the most powerful and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.


αMT Also known as:

  • 1-(1H-Indol-3-yl)-2-propanamin[German][ACD/IUPAC Name]
  • 1-(1H-Indol-3-yl)-2-propanamine[ACD/IUPAC Name]
  • 1-(1H-Indol-3-yl)-2-propanamine[French][ACD/IUPAC Name]
  • 1-(1H-indol-3-yl)propan-2-amine
  • 1H-Indole-3-ethanamine, α-methyl-
  • 1H-Indole-3-ethanamine, α-methyl-[ACD/Index Name]
  • 1-Methyl-2-(3-indolyl)ethylamine
  • 3-(2-Aminopropyl)indole
  • a-Methyltryptamine
  • BIK35ACJ0Q
  • Indole, 3- (2-aminopropyl)-
  • INDOPAN, (-)-
  • INDOPAN, (+)-
  • MFCD00005654
  • NL4550000
  • α-Methyltryptamine
  • (±)-α-Methyl-1H-indole-3-ethanamine
  • ??-methyltryptamine
  • [(2R)-1-(1H-indol-3-yl)propan-2-yl]ammonium
  • [2-(1H-indol-3-yl)-1-methylethyl]amine
  • [299-26-3]
  • 140457
  • 164 E
  • 164E
  • 1H-indole-3-ethanamine, a-methyl-
  • 1H-Indole-3-ethanamine, α-methyl
  • 1H-Indole-3-ethanamine, α-methyl- (9CI)
  • 1-indol-3-ylprop-2-ylamine
  • 2-(1H-Indol-3-yl)-1-methyl-ethylamine
  • 2-(1H-Indol-3-yl)-1-methyl-ethylamine (α-MeT, α-Methyltryptamine)
  • a-methyl-1H-Indole-3-ethanamine
  • AMT
  • DL-3-(2-aminopropyl)indole
  • DL-α-methyltryptamine
  • DL-α-Methyltryptamine
  • DL-α-Methyltryptamine free base
  • DL-α-Methyltryptamine, free base
  • Indole, 3-(2-aminopropyl)-
  • Indole, 3-(2-aminopropyl)-, (±)-
  • It-290 (dl)
  • IT-290(D,L)
  • IT-290(dl)
  • It-403 (D)
  • IT-403(D)
  • M-4620
  • NL 4555000
  • Ro 3-0926
  • Tryptamine, α-methyl
  • tryptamine, α-methyl-
  • U 14 (VAN)
  • U 14164 E
  • u-14164e (dl)
  • U-14164E(D,L)
  • U-14164E(dl)
  • WLN: T56 BMJ D1YZ1
  • α-Methyl-1H-indole-3-ethanamine
  • α-Methyl-3-indoleethanamine
  • α-Methyl-3-indoleethanamine
  • α-methyltryptamine
  • α-methyl-β-indolaethylamine
  • α-Methyl-β-indolaethylamine[German]
  • α-Methyl-β-indoleethylamine
  • α-Methyl-β-indoleethylamine

A long-acting psychedelic-empathogen with a broad method of action in the brain. Not suitable for combination with many other substances. Used as an anti-depressant in the Soviet Union, but later found popularity in the RC scene, mainly in the UK.


αMT was originally developed by Upjohn in the 1960s. It was briefly used in the Soviet Union as an antidepressant under the trade name Indopan. Indopan was prescribed in 5-10 mg doses, which is significantly lower than the dose used for recreational effects.

Erowid has received “a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) αMT ingestion. " There were 22 deaths linked to αMT in England and Wales where the drug became popular as a legal high from 2012 until it was banned in early 2015. Limited data exists about the pharmacological properties, metabolism, and toxicity of aMT, and it has a limited history of non-medical human use.

It is highly advised to use harm reduction practices if using this substance.




Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain.

AMT is substituted at the alpha carbon Rα of its tryptamine backbone with a methyl group. AMT is found in freebase form as a racemate of its (R-) and (S-) enantiomers.

Common NameAlpha-Methyltryptamine
Systematic nameα-Methyltryptamine
Std. InChi
Std. InChiKey
Avg. Mass174.2423 Da
Molecular Weight174.2423
Monoisotopic Mass174.115692 Da
Nominal Mass174
ChemSpider ID8930

Subscribe for the latest updates

Dose Chart


Duration Chart

αMT Duration Data
Onset30-90 minutes
Duration10-16 hours
After-effects6-12 hours



  1. Cannabis
    • Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics. Small amounts can reduce nausea with aMT but take care.
  2. Caffeine
    • High doses of caffeine may cause anxiety which is less manageable when tripping, and since both are stimulating the combination may cause some physical discomfort.
  3. Alcohol
    • aMT has a broad mechanism of action in the brain and so does alcohol so the combination can be unpredictable


    No Synergy

    1. Opioids
      • No unexpected interactions

    Auditory Effects

    Psychological Effects

    In comparison to more traditional psychedelics such as LSD, DMT and Psilocin, the AMT head space is described as not nearly as deep, insightful or profound. The total sum of these cognitive components regardless of the setting generally includes:

    Pharmacological Effects

    αMT’s psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. αMT also acts as a releasing agent of serotonin, noradrenaline, and dopamine. It also acts as a very weak, non-selective RIMA in-vitro and in-vivo., but this is unlikely to be very significant (if at all) with common doses.

    Physical Effects

    • Stimulation - Regarding its effects on the physical energy levels of the user, AMT tends to be very stimulating, resulting in jaw clenching and a shakiness and unsteadiness of the hands. The stimulation encourages the user to move around, run, dance, climb or engage in physical activities. In comparison, other common psychedelics such as psilocybin are sedating and relaxed.
    • Spontaneous bodily sensations - AMT's "body high" can be described as an intense and constant all-encompassing sensation. In comparison to other psychedelics, this sensation does not manifest itself in the form of a continuously shifting tingling sensation that travels up and down the body spontaneously; it is instead felt like an extended, unchanging activation of every nerve ending on the body that lasts throughout the entire duration of the experience. This continuous sensation is immensely pleasurable but can become overwhelmingly intense and almost a burden at higher levels.
    • Difficulty urinating - A slight difficulty urinating is occasionally present.
    • Temperature regulation suppression
    • Headaches - Many people report headaches towards the end of the experience.
    • Abnormal heartbeat
    • Increased blood pressure
    • Increased heart rate
    • Increased perspiration
    • Nausea - Moderate to extreme nausea is commonly reported. This either passes once the user has vomited or gradually fades by itself as the peak sets in.
    • Pupil dilation

    Subjective Effects

    Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

    Visual Effects

    The visual effects of AMT are mostly present only when large doses have been consumed and are proportionally mild in comparison to the intensity of its accompanying cognitive and physical effects when compared to substances such as LSD and psilocin.




    The visual geometry produced by aMT can be described as more similar in appearance to that of Psilocin, and 2C-E than LSD. At lower levels it can appear to be bland and simplistic in complexity but becomes equal regarding intricacy and depth to that of any of the classical psychedelics at higher doses. It can be comprehensively described with its variations as intricate in complexity (at heavy dosages), abstract in form, organic in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, equal in soft and sharp edges, small in size, fast in speed, smooth in motion, equal in round and angular corners, non-immersive in depth, and consistent in intensity. At higher dosages, the visual geometry is significantly more likely to result in states of Level 8B geometry over Level 8A.

    Hallucinatory states

    • Transformations
    • Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This particular effect is uncommon during the first half of the trip but capable of manifesting itself towards the end of the experience, particularly if sleep deprivation starts to take its toll due to the abnormally long duration. The internal hallucinations are more common within dark environments and can be comprehensively described through their variations as lucid in believability, fixed in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.

    Legal Status

  1. Australia: AMT is illegal to possess, produce and sell.
  2. Austria: AMT is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
  3. Canada: Canada has no mention of this substance in the Controlled substances and Substances Act.
  4. Germany: AMT is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of January 31, 1993. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
  5. Greece: AMT is illegal to possess, produce and sell.
  6. Japan: AMT is illegal to possess, produce and sell.
  7. Latvia: AMT is a Schedule I drug.
  8. Russia: AMT is illegal to possess, produce and sell.
  9. Sweden: AMT is illegal to possess, produce and sell.
  10. United Kingdom: AMT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.
  11. United States: AMT is a Schedule I drug.
  12. Sources


    1. Erowid Online Books : TIHKAL - #48 a-MT |
    2. US Patent 3296072 - Method of Treating Mental Depression
    3. AMT's TiHKAL entry by Alexander Shulgin (IsomerDesign)
    4. Donald G. Barceloux (20 March 2012). Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. John Wiley & Sons. pp. 196–.  978-0-471-72760-6.
    5. Leslie Iversen (11 November 2013). Handbook of Psychopharmacology: Volume 14 Affective Disorders: Drug Actions in Animals and Man. Springer Science & Business Media. pp. 132–.  978-1-4613-4045-4.
    6. Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders. Academic Press. 17 May 2013. pp. 632–.  978-0-12-398360-2.
    7. AMT (Alphamethyltryptamine, IT-290) Fatalities / Deaths by Erowid |
    8. Deaths Related to Drug Poisoning, England and Wales, 2016 release (table 8) |
    10. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain |
    11. In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes |
    12. Studies of Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase II. Inhibition by α-Methylated Substrate-Analogue Monoamines, α-Methyltryptamine, α-Methylbenzylamine and Two Enantiomers of α-Methylbenzylamine |
    14. Boland DM, Andollo W, Hime GW, Hearn WL. “Fatality due to acute alpha-methyltryptamine intoxication”. J Anal Toxicol. 2005 Jul-Aug;29(5):394-7. |
    15. Reduction in brain serotonin markers by α-ethyltryptamine (Monase) (ScienceDirect) |
    16. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity |
    17. CSDA |
    18. "Vierte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
    19. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    20. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    21. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) |
    22. Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor |
    23. Misuse of Drugs Act 1971 ( |
    24. Drug Enforcement Administration |

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks to ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.